Company Overview and News
KUALA LUMPUR (Oct 8): Based on corporate announcements and news flow today, companies in focus on Tuesday (Oct 9) may include: UEM Sunrise Bhd, T7 Global Bhd, Reach Energy Bhd, MMC Corp Bhd, Gamuda Bhd, MCE Holdings Bhd and IHH Healthcare Bhd.
5148 5225 7245 Q0F IHHHF 5256 0131 5001
KUALA LUMPUR (Oct 8): UEM Sunrise Bhd (UEMS) today said its chief operating officer for development Datuk Roslan Ibrahim is relinquishing his role following his transfer to UEM Group Bhd.
5148 BSMAF 1818
New landmark: (from left) Multiplex regional MD Graham Cottam, Malaysia consul general Westmoreland Palon, KHK Group MD Jo Jo Kong, Fajarbaru Builder Group executive director Datuk Seri Eric Kuan, Victoria Minister of Industry and Employment Ben Carroll, Jiaheng, Beulah executive director Adelene Teh and Fender Katsalidis Architects founder partner Karl Fender at the groundbreaking ceremony of Paragon development.
KUALA LUMPUR (Oct 2): UEM Sunrise will launch a low-density condominium in Mont'Kiara here comprising only 240 units in the middle of this month, said its managing director and CEO Anwar Syahrin Abdul Ajib.
KUALA LUMPUR (Oct 2): UEM Sunrise Bhd is studying if it is even possible to reduce property prices thanks to exemptions on certain construction materials and services from the Sales and Service Tax (SST) on property prices as any savings may be offset by the rise of other construction costs.
KUALA LUMPUR (Oct 2): UEM Sunrise Bhd (UEMS) has inked a memorandum of understanding (MoU) with GPay Network Sdn Bhd, Grabcar Sdn Bhd and MyTeksi Sdn Bhd (Grab Partners) to collaborate on services.
5148 BSMAF 1818
From left: Grab Malaysia country head Sean Goh, GrabPay Malaysia, Singapore and Philippines head Ooi Huey Tyng and Anwar.
In a filing with Bursa Malaysia, UEM Sunrise said Izzaddin has also ceased to be the company’s board tender committee chairman and member of the board development committee, as well as the ESOS Committee of the company effective Oct 1
4863 5148 1368 MYTEF BSMAF 1818
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...